Bottom line
GMAJX vs GSBGX: the short answer
GMAJX (GMO Emerging Country Debt Shares Fund) and GSBGX (GMO Small Cap Quality Fund) are both mutual funds.
But GSBGX is far broader, holding 46 positions to 2 for GMAJX, so beyond the top names it adds exposure GMAJX doesn't have.
GSBGX is cheaper at 0.67% vs 0.8% — a difference of $13 a year per $10,000 invested.
Over one year, GMAJX returned +20.3% vs −1.4% for GSBGX.
Updated Nov 19, 2026
GMAJX vs GSBGX side by side
| GMAJX | GSBGX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Gmo | Gmo |
| Category | Emerging Markets | Small-Cap |
| Expense ratio | 0.8% | 0.67% |
| Annual cost per $10k | $80 | $67 |
| 10-yr cost on $10k (prospectus) | — | $890 |
| Max front load | — | — |
| 12b-1 fee | — | — |
| 1-yr return | +20.3% | −1.4% |
| 5-yr return (annualized) | +5.7% | — |
| 10-yr return (annualized) | +6.8% | — |
| Best quarter | +12.5% | +13.1% |
| Worst quarter | −14.5% | −9.8% |
| Net assets (fund) | $61.8M | $702.0M |
| Number of holdings | 2 | 46 |
| Portfolio turnover | % | 72% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GMAJX | GSBGX | Difference |
|---|---|---|---|
| 2025 | +22.2% | −1.4% | +23.6% |
| 2024 | +13.2% | +9.4% | +3.9% |
| 2023 | +17.5% | +32.8% | −15.3% |
Source: Fund prospectus bar charts
Holdings overlap
GMAJX and GSBGX share none of their top holdings.
GMAJX top 10
- GMO Emerging Country Debt — 100.04%
- State Street Global Advisors — 0.03%
GSBGX top 10
- Aramark — 4.81%
- PriceSmart Inc — 4.73%
- Cirrus Logic Inc — 4.36%
- AAON Inc — 3.83%
- Balchem Corp — 3.59%
- Globus Medical Inc — 3.54%
- Clean Harbors Inc — 3.44%
- Ollie's Bargain Outlet Holdings Inc — 3.25%
- New York Times Co/The — 3.22%
- AptarGroup Inc — 3.20%
FAQ
What is the difference between GMAJX and GSBGX?
Which is cheaper, GMAJX or GSBGX?
Should I own both GMAJX and GSBGX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.